title: Diabetic nephropathy: traditional to proteomic markers.
abstract: Diabetic nephropathy (DN) is one of the major microvascular complications of diabetes and it is defined as a rise in the urinary albumin excretion (UAE) rate and abnormal renal function. Currently, changes in albuminuria are considered a hallmark of onset or progression of DN. However, some patients with diabetes have advanced renal pathological changes and progressive kidney function decline even if urinary albumin levels are in the normal range, indicating that albuminuria is not the perfect marker for the early detection of DN. The present article provides an overview of the literature reporting some relevant biomarkers that have been found to be associated with DN and that potentially may be used to predict the onset and/or monitor the progression of nephropathy. In particular, biomarkers of renal damage, inflammation, and oxidative stress may be useful tools for detection at an early stage or prediction of DN. Proteomic-based biomarker discovery represents a novel strategy to improve diagnosis, prognosis and treatment of DN; however, proteomics-based approaches are not yet available in most of the clinical chemistry laboratories. The use of a panel with a combination of biomarkers instead of urinary albumin alone seems to be an interesting approach for early detection of DN, including markers of glomerular damage (e.g., albumin), tubular damage (e.g., NAG and KIM-1), inflammation (e.g., TNF-α) and oxidative stress (e.g., 8-OHdG) because these mechanisms contribute to the development and outcomes of this disease.
authors.affiliation: Laboratório de Pesquisa em Bioquímica Clínica, Departamento de Análises Clínicas e Toxicológicas, Centro de Ciências da Saúde, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil. rnmoresco@yahoo.com.br
authors.forename: Rafael N
authors.initials: RN
authors.lastname: Moresco
authors.forename: Manuela B
authors.initials: MB
authors.lastname: Sangoi
authors.forename: José A M
authors.initials: JA
authors.lastname: De Carvalho
authors.forename: Etiane
authors.initials: E
authors.lastname: Tatsch
authors.forename: Guilherme V
authors.initials: GV
authors.lastname: Bochi
mesh_terms: D000080242:8-Hydroxy-2'-Deoxyguanosine; D000118:Acetylglucosaminidase / Q000652:urine; D000419:Albuminuria / Q000175:diagnosis* / Q000473:pathology / Q000652:urine; D015415:Biomarkers / Q000652:urine; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000652:urine; D003928:Diabetic Nephropathies / Q000175:diagnosis* / Q000473:pathology / Q000652:urine; D018450:Disease Progression; D042241:Early Diagnosis; D000072596:Hepatitis A Virus Cellular Receptor 1; D006801:Humans; D007249:Inflammation; D007668:Kidney / Q000378:metabolism* / Q000473:pathology; D008562:Membrane Glycoproteins / Q000652:urine; D009363:Neoplasm Proteins / Q000652:urine; D018384:Oxidative Stress; D011379:Prognosis; D040901:Proteomics; D011991:Receptors, Virus; D014409:Tumor Necrosis Factor-alpha / Q000652:urine
chemical_list: D015415:Biomarkers; C491143:HAVCR1 protein, human; D000072596:Hepatitis A Virus Cellular Receptor 1; D008562:Membrane Glycoproteins; C117339:NBAS protein, human; D009363:Neoplasm Proteins; D011991:Receptors, Virus; D014409:Tumor Necrosis Factor-alpha; D000080242:8-Hydroxy-2'-Deoxyguanosine; D000118:Acetylglucosaminidase; D003849:Deoxyguanosine